162 related articles for article (PubMed ID: 37948590)
1. Reappraisal of cardiovascular risk factors in patients with chronic myeloproliferative neoplasms.
Krecak I; Verstovsek S; Lucijanic M
Clin Adv Hematol Oncol; 2023 Oct; 21(10):541-548. PubMed ID: 37948590
[TBL] [Abstract][Full Text] [Related]
2. Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives.
Krecak I; Verstovsek S; Lucijanic M
Ann Hematol; 2024 May; 103(5):1513-1523. PubMed ID: 37665349
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risk in a contemporary cohort of patients with myeloproliferative neoplasms'.
Mehta D; Alimam S; McLornan DP; Henry JA; Ahmed S; Ghosh AK; Tyebally S; Walker JM; Patel R; Amerikanou R; O'Nions J; Wilson AJ; Lambert J; Sekhar M; Chen D
Curr Res Transl Med; 2024 Mar; 72(1):103420. PubMed ID: 38262189
[TBL] [Abstract][Full Text] [Related]
4. Antecedent cardiovascular disease and autoimmunity in Philadelphia-negative chronic myeloproliferative neoplasms.
Sørensen AL; Hasselbalch HC
Leuk Res; 2016 Feb; 41():27-35. PubMed ID: 26718091
[TBL] [Abstract][Full Text] [Related]
5. Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms.
Büttner-Herold M; Sticht C; Wiech T; Porubsky S
Histopathology; 2021 Apr; 78(5):738-748. PubMed ID: 33078472
[TBL] [Abstract][Full Text] [Related]
6. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.
Rungjirajittranon T; Owattanapanich W; Ungprasert P; Siritanaratkul N; Ruchutrakool T
BMC Cancer; 2019 Feb; 19(1):184. PubMed ID: 30819138
[TBL] [Abstract][Full Text] [Related]
7. How I Manage Thrombotic/Thromboembolic Complications in Myeloproliferative Neoplasms.
Koschmieder S
Hamostaseologie; 2020 Feb; 40(1):47-53. PubMed ID: 32050290
[TBL] [Abstract][Full Text] [Related]
8. Thrombotic and bleeding complications in classical myeloproliferative neoplasms.
McMahon B; Stein BL
Semin Thromb Hemost; 2013 Feb; 39(1):101-11. PubMed ID: 23264112
[TBL] [Abstract][Full Text] [Related]
9. Risk of Wernicke's encephalopathy and cardiac disorders in patients with myeloproliferative neoplasm.
Wu J; Zhang L; Vaze A; Lin S; Juhaeri J
Cancer Epidemiol; 2015 Apr; 39(2):242-9. PubMed ID: 25736368
[TBL] [Abstract][Full Text] [Related]
10. Myeloproliferative Neoplasms in Children and Adolescents and Thrombosis at Unusual Sites: The Role of Driver Mutations.
Tafesh L; Musgrave K; Roberts W; Plews D; Carey P; Biss T
J Pediatr Hematol Oncol; 2019 Aug; 41(6):490-493. PubMed ID: 29668539
[TBL] [Abstract][Full Text] [Related]
11. Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms.
Seguro FS; Teixeira LLC; da Rosa LI; da Silva WF; Nardinelli L; Bendit I; Rocha V
J Thromb Thrombolysis; 2020 May; 49(4):667-672. PubMed ID: 31898273
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk factor in MPN patients.
Accurso V; Santoro M; Mancuso S; Siragusa S
J Thromb Thrombolysis; 2020 Oct; 50(3):640-641. PubMed ID: 32002767
[No Abstract] [Full Text] [Related]
13. Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms.
Falanga A; Marchetti M; Schieppati F
Hamostaseologie; 2021 Feb; 41(1):48-57. PubMed ID: 33588455
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and management strategies for Myeloproliferative Neoplasm-Unclassifiable (MPN-U): An international survey of contemporary practice.
Hargreaves R; Harrison CN; McLornan DP
Curr Res Transl Med; 2022 Jul; 70(3):103338. PubMed ID: 35217310
[TBL] [Abstract][Full Text] [Related]
15. Myeloproliferative neoplasms in adolescents and young adults.
Amerikanou R; Lambert J; Alimam S
Best Pract Res Clin Haematol; 2022 Jun; 35(2):101374. PubMed ID: 36333071
[TBL] [Abstract][Full Text] [Related]
16. [Myeloproliferative neoplasms related glomerulopathy].
Paule R; Ponsoye M; Gueutin V; Deray G; Izzedine H
Rev Med Interne; 2013 Jun; 34(6):369-72. PubMed ID: 23357690
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms.
Guy A; Poisson J; James C
Leukemia; 2021 Apr; 35(4):935-955. PubMed ID: 33658660
[TBL] [Abstract][Full Text] [Related]
18. Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey.
Yu J; Parasuraman S; Paranagama D; Bai A; Naim A; Dubinski D; Mesa R
BMC Cancer; 2018 Apr; 18(1):420. PubMed ID: 29653557
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Events: A Challenge in JAK2-positive Myeloproliferative Neoplasms.
Haybar H; Khodadi E; Shahjahani M; Saki N
Cardiovasc Hematol Disord Drug Targets; 2017; 17(3):161-166. PubMed ID: 29086702
[TBL] [Abstract][Full Text] [Related]
20. Thrombosis in myeloproliferative neoplasms.
Falanga A; Marchetti M
Semin Thromb Hemost; 2014 Apr; 40(3):348-58. PubMed ID: 24610470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]